Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
AMD 3100 octahydrochloride (HB2739)
Description:Potent, selective CXCR4 antagonist. Mobilizes hematopoietic stem cells.
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Mifepristone (HB2783)
Description:Potent glucocorticoid and progesterone receptor antagonist. Also used for gene editing as a mifepristone inducible Cas9 and Cpf1 CRISPR effector.
Purity:>99%
Tamoxifen (HB0601)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>99%
Tamoxifen Citrate (HB0602)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9). Citrate salt.
Purity:>98%